Drug class profile · refreshed daily from federal data

Methylxanthine

1 molecule in this class, — combined CY2024 Part D spend across — claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 15 Oct 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Methylxanthine class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: —combined across class
Total Rx claims: —— unique beneficiaries
Generic mfrs (active): 18across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Theophylline

Brand: Theo-24 · — Part D claims (CY24) · First FDA approval: 2006-04-21

18 generic mfrs 0 plans require PA

Low NADAC$0.112

→

Avg plan cost$1.44

Part D spend — 13× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.